Abbott Will Present Two-Year Follow-Up Data At Xience FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Abbott expects to present two-year data for several hundred Xience V everolimus-eluting stent patients at a Nov. 29 meeting with an FDA advisory panel, the firm announced Oct. 17